1. Immune checkpoint analysis in lip cancer
- Author
-
C. Hallermann, Ali Modabber, F. Pannier, M. Klein, Kai Wermker, and Frank Hölzle
- Subjects
Oncology ,medicine.medical_specialty ,Metastasis ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,0302 clinical medicine ,PD-L1 ,Internal medicine ,Tumor Microenvironment ,medicine ,Humans ,Tumor microenvironment ,biology ,business.industry ,FOXP3 ,030206 dentistry ,Prognosis ,medicine.disease ,Immunohistochemistry ,Immune checkpoint ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Lip Neoplasms ,Carcinoma, Squamous Cell ,biology.protein ,Surgery ,Oral Surgery ,NODAL ,business ,CD8 - Abstract
The aim of this study was to establish whether PD-L1, PD-1, and markers of the tumor microenvironment (CD4, CD8, FOXP3) could have a prognostic value in squamous cell carcinoma of the lip (LSCC). In patients with histologically proven LSCC, tumor specimens were stained using immunohistochemistry (for PD-1, PD-L1, CD4, CD8, and FOXP3) on paraffin-embedded tissues. Patients with (N+) and without (N−) nodal metastasis were stratified and matched to each other according to prognostically relevant clinicopathological parameters. 58 patients (29 N+ and 29 N−) were included. PD-L1 expression was positive (>1%) in 56.1% (n = 33) of all LSCC cases, but its expression did not differ significantly between metastasis groups (65.5% in N+ versus 48.3% in N−; p = 0.144). Nodal disseminated LSCC showed a tendency for higher PD-L1 expression. None of the analyzed markers showed significant correlation with the risk for nodal disease, or revealed significant prognostic value. Due to their significant expression, PD-L1 and PD-1 are potential targets for checkpoint inhibitor therapy in LSCC. Their expression should be analyzed in advanced and metastasized LSCC cases.
- Published
- 2021
- Full Text
- View/download PDF